Publications
36
Citations
370
Est. group size
~12
Recurring co-author estimate
Active years
17
Publishing since 2010
Jeremy Sen's work focuses on the clinical care of patients with blood cancers, including leukemia, lymphoma, and those undergoing stem cell or CAR-T cell transplants. Much of the research addresses practical treatment issues such as preventing infections and side effects, improving chemotherapy protocols, and evaluating drug therapies to make cancer treatment safer and more efficient. This research is largely applied and hospital-based, often involving multi-institution collaborations and quality-improvement studies.
Publication output has fluctuated over the past decade, with a peak in 2018, a slower period around 2023-2024, and a recent increase in 2025-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Permissive Cardiotoxicity: Real World Outcomes of CAR-T Therapy in Patients with Heart Failure and Reduced Ejection Fraction
Transplantation and Cellular Therapy · 2026
- Reduced Dose Post-Transplant Cyclophosphamide in Allogeneic Hematopoietic Cell Transplant
Transplantation and Cellular Therapy · 2026
- Evaluation of palonosetron, fosaprepitant, and olanzapine as antiemetic prophylaxis for fludarabine and melphalan-based conditioning regimens prior to allogeneic hematopoietic stem cell transplants
Leukemia Research · 2023
- ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
Clinical Lymphoma Myeloma & Leukemia · 2022
- Poster: ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
Clinical Lymphoma Myeloma & Leukemia · 2022
- Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Blood · 2021
- Variant Acute Promyelocytic Leukemia Presenting Without Auer Rods Highlights the Need for Correlation with Cytogenetic Data in Leukemia Diagnosis
Laboratory Medicine · 2021
- Reducing length of stay for patients with acute myeloid leukemia receiving inpatient high-dose cytarabine consolidation chemotherapy.
Journal of Clinical Oncology · 2021
- Reducing Length of Stay for Patients with Acute Myeloid Leukemia Receiving Inpatient High-Dose Cytarabine Consolidation Chemotherapy
Blood · 2021
- Prospective Initiative to Reduce Mucosal Barrier Injuries and Bloodstream Infections in Patients With Hematologic Malignancy Receiving Inpatient Chemotherapy
JCO Oncology Practice · 2020
- CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
Blood · 2020
- Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients
Journal of Oncology Pharmacy Practice · 2020
- <p>A prospective study on urine alkalization with an oral regimen consisting of sodium bicarbonate and acetazolamide in patients receiving high-dose methotrexate</p>
Cancer Management and Research · 2019
- Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines
Journal of Oncology Pharmacy Practice · 2019
- Multidisciplinary Effort to Decrease Time From Admission to Chemotherapy on an Inpatient Oncology Unit
Journal of Oncology Practice · 2019
- Blood×10
- Transplantation and Cellular Therapy×6
- Clinical Lymphoma Myeloma & Leukemia×3
- Journal of Clinical Oncology×3
- Journal of Oncology Pharmacy Practice×2
- Basem M. William
Medicine · The Ohio State University
- Jonathan E. Brammer
Medicine · The Ohio State University
- Sonia Godbole
Medicine · The Ohio State University
- Emily Dotson
Medicine · The Ohio State University
- Carl Quinion
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile